9.83
price up icon4.35%   0.41
after-market アフターアワーズ: 9.83
loading
前日終値:
$9.42
開ける:
$9.35
24時間の取引高:
3.92M
Relative Volume:
0.96
時価総額:
$2.56B
収益:
$6.29B
当期純損益:
$750.00M
株価収益率:
3.4132
EPS:
2.88
ネットキャッシュフロー:
$586.00M
1週間 パフォーマンス:
+6.85%
1か月 パフォーマンス:
+0.82%
6か月 パフォーマンス:
-31.50%
1年 パフォーマンス:
-55.48%
1日の値動き範囲:
Value
$9.35
$9.87
1週間の範囲:
Value
$8.99
$9.87
52週間の値動き範囲:
Value
$8.01
$22.42

Organon Co Stock (OGN) Company Profile

Name
名前
Organon Co
Name
セクター
Healthcare (1150)
Name
電話
551-430-6000
Name
住所
30 HUDSON STREET, JERSEY CITY
Name
職員
10,000
Name
Twitter
Name
次回の収益日
2024-10-31
Name
最新のSEC提出書
Name
OGN's Discussions on Twitter

OGN を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Drug Manufacturers - General icon
OGN
Organon Co
9.83 2.45B 6.29B 750.00M 586.00M 2.88
Drug Manufacturers - General icon
LLY
Lilly Eli Co
737.83 656.73B 53.26B 13.80B -50.20M 15.30
Drug Manufacturers - General icon
JNJ
Johnson Johnson
178.00 426.69B 90.62B 22.66B 18.18B 9.35
Drug Manufacturers - General icon
ABBV
Abbvie Inc
211.86 371.68B 58.33B 3.73B 18.24B 2.10
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
128.23 244.98B 53.40B 13.68B 16.89B 6.9231
Drug Manufacturers - General icon
MRK
Merck Co Inc
84.18 210.11B 63.43B 16.42B 14.72B 6.49

Organon Co Stock (OGN) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-05-02 ダウングレード Evercore ISI Outperform → In-line
2024-09-06 ダウングレード JP Morgan Neutral → Underweight
2023-11-03 ダウングレード Goldman Buy → Neutral
2023-09-21 開始されました Barclays Overweight
2023-03-16 開始されました Raymond James Outperform
2022-10-14 ダウングレード BofA Securities Neutral → Underperform
2022-09-06 アップグレード Piper Sandler Neutral → Overweight
2022-08-05 ダウングレード BofA Securities Buy → Neutral
2022-04-27 開始されました Goldman Buy
2022-04-06 再開されました Morgan Stanley Equal-Weight
2021-10-07 開始されました Piper Sandler Neutral
2021-09-01 開始されました BofA Securities Buy
2021-07-22 開始されました Citigroup Buy
2021-06-15 開始されました JP Morgan Neutral
2021-06-11 開始されました Morgan Stanley Equal-Weight
2021-06-10 開始されました Evercore ISI Outperform
すべてを表示

Organon Co (OGN) 最新ニュース

pulisher
11:00 AM

Organon And Henlius Are Latest To Receive Denosumab Nod In US - insights.citeline.com

11:00 AM
pulisher
Sep 02, 2025

Organon and Henlius get FDA nod for Amgen biosimilars (OGN) - Seeking Alpha

Sep 02, 2025
pulisher
Sep 02, 2025

Major Breakthrough: FDA Approves Two New Biosimilars to Treat Millions with Bone Health Conditions - Stock Titan

Sep 02, 2025
pulisher
Sep 01, 2025

Organon's Upside Potential: Can Biosimilars and Women’s Health Drive a Re-rating? - AInvest

Sep 01, 2025
pulisher
Sep 01, 2025

Will Raised Revenue Guidance and New Launches Shift Organon's (OGN) Growth Outlook? - simplywall.st

Sep 01, 2025
pulisher
Sep 01, 2025

How Investors Are Reacting To Organon (OGN) Lifting 2025 Guidance and CEO Share Purchase - Yahoo Finance

Sep 01, 2025
pulisher
Aug 30, 2025

Organon & Co. (OGN) Advances VTAMA Cream, Strengthens Women’s Health Portfolio - MSN

Aug 30, 2025
pulisher
Aug 25, 2025

Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance

Aug 25, 2025
pulisher
Aug 24, 2025

Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know - MSN

Aug 24, 2025
pulisher
Aug 20, 2025

Organon & Co. shares rise 1.57% intraday after Trane Technologies launches Season 5 of Healthy Spaces podcast. - AInvest

Aug 20, 2025
pulisher
Aug 19, 2025

Organon & Co. shares fall 1.02% intraday after Genentech files BPCIA complaint against Organon and Henlius. - AInvest

Aug 19, 2025
pulisher
Aug 19, 2025

Henlius And Organon Sued In US Over Plans To Market Perjeta Biosimilar - insights.citeline.com

Aug 19, 2025
pulisher
Aug 18, 2025

Does Organon's Raised 2025 Guidance Signal a Turning Point for OGN Investors? - simplywall.st

Aug 18, 2025
pulisher
Aug 16, 2025

Kahn Brothers' Q2 2025 13F Filing: Alphabet, Comcast, and Organon Highlights - AInvest

Aug 16, 2025
pulisher
Aug 16, 2025

Organon in charts: Women's Health revenue up ~3% Y/Y in Q2 - MSN

Aug 16, 2025
pulisher
Aug 15, 2025

Roche Sues Organon in First Case Over Biosimilar Copy of Perjeta - Bloomberg Law News

Aug 15, 2025
pulisher
Aug 15, 2025

There May Be Some Bright Spots In Organon's (NYSE:OGN) Earnings - Yahoo Finance

Aug 15, 2025
pulisher
Aug 14, 2025

Organon & Co. (OGN) Stock Price, News & Analysis - MarketBeat

Aug 14, 2025
pulisher
Aug 14, 2025

Daré Bioscience Posts Narrower Q2 Loss - The Motley Fool

Aug 14, 2025
pulisher
Aug 14, 2025

OGN’s Market Whiplash: -52.64% YTD Decline, -4.30% Plunge in 30 Days - investchronicle.com

Aug 14, 2025
pulisher
Aug 14, 2025

Bullish Organon Insiders Loaded Up On US$651.6k Of Stock - 富途牛牛

Aug 14, 2025
pulisher
Aug 14, 2025

Organon & Co.'s Q2 2025 Earnings Call: Unraveling Key Contradictions in Capital Allocation, Nexplanon Growth, and Financial Forecasts - AInvest

Aug 14, 2025
pulisher
Aug 14, 2025

LPL Financial LLC Has $4.87 Million Holdings in Organon & Co. (NYSE:OGN) - Defense World

Aug 14, 2025
pulisher
Aug 13, 2025

NYSE: OGN Lawsuit Alert: Investors who lost money with Organon & Co. (NYSE: OGN) shares should contact the Shareholders Foundation - The Malaysian Reserve

Aug 13, 2025
pulisher
Aug 13, 2025

Ex-Dividend Reminder: Cencora, Organon and Esquire Financial Holdings - Nasdaq

Aug 13, 2025
pulisher
Aug 13, 2025

5 Must-Read Analyst Questions From Organon’s Q2 Earnings Call - Yahoo Finance

Aug 13, 2025
pulisher
Aug 13, 2025

OGN Q2 Deep Dive: Flat Sales, Margin Pressure, and Strategic Shifts Highlight Quarter - Yahoo Finance

Aug 13, 2025
pulisher
Aug 12, 2025

Organon's Valuation: Discounted Due to Structural Challenges - AInvest

Aug 12, 2025
pulisher
Aug 12, 2025

Organon: Valuation Discount Offset By Structural Headwinds (NYSE:OGN) - Seeking Alpha

Aug 12, 2025
pulisher
Aug 12, 2025

Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know - MSN

Aug 12, 2025
pulisher
Aug 11, 2025

Natixis Advisors LLC Has $778,000 Holdings in Organon & Co. (NYSE:OGN) - Defense World

Aug 11, 2025
pulisher
Aug 10, 2025

Organon & Co. (OGN): Assessing Dividend Sustainability and Valuation Amid Earnings Pressures and Strategic Catalysts - AInvest

Aug 10, 2025
pulisher
Aug 10, 2025

Read This Before Considering Organon & Co. (NYSE:OGN) For Its Upcoming US$0.02 Dividend - uk.finance.yahoo.com

Aug 10, 2025
pulisher
Aug 08, 2025

Organon & Co. (OGN) Reports Q2 2025 Results - MSN

Aug 08, 2025
pulisher
Aug 08, 2025

Organon Q2 Preview: What to expect? - MSN

Aug 08, 2025
pulisher
Aug 08, 2025

Organon & Co. (NYSE:OGN) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World

Aug 08, 2025
pulisher
Aug 07, 2025

Organon & Co. Reports Q2 2025 Earnings, Raises Full-Year Guidance - AInvest

Aug 07, 2025
pulisher
Aug 07, 2025

Organon & Co. (NYSE:OGN) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year - Yahoo Finance

Aug 07, 2025
pulisher
Aug 07, 2025

Organon & Co. Reports Q2 2025 Financial Results - The Globe and Mail

Aug 07, 2025
pulisher
Aug 06, 2025

Organon & Co. Earnings Call: Resilience Amid Challenges - The Globe and Mail

Aug 06, 2025
pulisher
Aug 06, 2025

Organon (OGN) Fiscal Q2 Revenue Beats 1% - AOL.com

Aug 06, 2025
pulisher
Aug 06, 2025

Organon & Co. (OGN) Slashes 13.13% on Disappointing Earnings - MSN

Aug 06, 2025
pulisher
Aug 06, 2025

Organon Q2 Earnings: It May Be Time To Desert This Sinking Ship (Downgrade) (NYSE:OGN) - Seeking Alpha

Aug 06, 2025
pulisher
Aug 06, 2025

Endometriosis Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Organon, Ironwood Pharma, Mitsubishi Tanabe Pharma Corp, AbbVie/Neurocrine Biosciences - The Globe and Mail

Aug 06, 2025
pulisher
Aug 06, 2025

Organon & Co. SEC 10-Q Report - TradingView

Aug 06, 2025
pulisher
Aug 06, 2025

Organon & Co. (NYSE:OGN) Q2 2025 Earnings Call Transcript - Insider Monkey

Aug 06, 2025
pulisher
Aug 06, 2025

Organon jumps despite Q2 revenue dip as revised outlook exceeds consensus - MSN

Aug 06, 2025
pulisher
Aug 06, 2025

Organon Reports Results for the Second Quarter Ended June 30, 2025 - BioSpace

Aug 06, 2025
pulisher
Aug 06, 2025

ORGANON SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Organon & Co.OGN - Discover 361

Aug 06, 2025
pulisher
Aug 06, 2025

Organon & Co (OGN) Q2 2025 Earnings Call Highlights: Navigating Challenges with Strategic Growth By GuruFocus - Investing.com Canada

Aug 06, 2025

Organon Co (OGN) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
drug_manufacturers_general SNY
$49.89
price up icon 0.63%
$112.99
price up icon 0.25%
drug_manufacturers_general PFE
$24.79
price down icon 0.76%
$283.85
price down icon 1.07%
drug_manufacturers_general NVO
$56.74
price up icon 0.64%
drug_manufacturers_general MRK
$84.18
price down icon 1.52%
大文字化:     |  ボリューム (24 時間):